Top

Published in:

Open Access 01-02-2013 | Preclinical Study

Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival

Authors: Gabriela Oprea-Ilies, Erhard Haus, Linda Sackett-Lundeen, Yuan Liu, Lauren McLendon, Robert Busch, Amy Adams, Cynthia Cohen

Published in: Breast Cancer Research and Treatment | Issue 3/2013

Abstract

In the normal rodent breast, the pineal hormone melatonin controls the development of ductal and alveolar tissue. Melatonin counteracts tumor occurrence and tumor cell progression in vivo and in vitro in animal and human breast cancer cell cultures. It acts predominantly through its melatonin MT1 receptor. Our aim was to investigate the presence or absence of the MT1 melatonin receptor in the aggressive triple negative group of human breast carcinoma (TNBC) and its possible relationship to the course of the disease. A total of 167 patients with a ER−, PR−, Her-2/neu− phenotype in which tissue for receptor studies was available were examined. The MT1 receptor immunostain was evaluated semiquantitatively as staining intensity (0, 1, 2, 3), percentage of stained cells and the weighted index (WI) (staining intensity times percentage of stained cells). A score of WI < 60 was regarded as “negative”. There was a striking difference in incidence of MT1 positivity and staining intensity between carcinomas in African American (AA) and Caucasian (C) women. The AA showed a higher incidence of MT1 negative tumors (41/84 = 48.8 % in AA, 6/51 = 11.8 % in C) and a lower average WI. MT1 positivity in TNBC was associated with a lower stage and a smaller tumor size at time of diagnosis. In multivariable survival analysis, MT1 negative TNBC in all cases regardless of race showed a significantly higher hazard ratio for disease progression, shorter progression free survival, and disease-related death, and shorter OS. This was especially pronounced in the AA group but did not reach statistical significance in the smaller group of C alone. These results suggest that melatonin or a melatonin receptor agonist may be useful biologic additions in the treatment of some forms of TNBC, especially in AA who generally show a more aggressive course of their disease.

Reiter RJ (1991) Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 12:151–180. doi:10.1210/edrv-12-2-151 PubMedCrossRef

Reiter RJ (1993) The melatonin rhythms: both a clock and a calendar. Experientia 49:654–664PubMedCrossRef

Reiter RJ, Tan DX, Jou MJ, Korkmaz A, Manchester LC, Paredes SD (2008) Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites (Review). Neuro Endocrinol Lett 29:391–398PubMed

Dubocovich ML, Markowska M (2005) Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 27:101–110. doi:10.1385/ENDO:27:2:101 PubMedCrossRef

Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J (2010) International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 62:343–380. doi:10.1124/pr.110.002832 PubMedCrossRef

Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L (2009) Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther 8:337–346PubMedCrossRef

Blask DE, Sauer LA, Dauchy RT (2002) Melatonin as a chronobiotic anti-cancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy (Review). Curr Top Med Chem 2:113–132PubMedCrossRef

Hill SM, Blask DE (1988) Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 48:6121–6126PubMed

Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Kranse JA, Sauer LA, Rivera-Bermudez MA, Dubocovich ML, Jasser SA, Lynch DT, Rollag MD, Zallatan F (2005) Melatonin depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 65:11174–11184. doi:10.1158/0008-5472.CAN-05-1945 PubMedCrossRef

10.

Dauchy RT, Dauchy EM, Sauer LA, Blask DE, Davidson LK, Krause JA, Lynch DT (2004) Differential inhibition of fatty acid transport in tissue-isolated steroid receptor negative human breast cancer xenografts perfused in situ with isomers of conjugated linoleic acid. Cancer Lett 209:7–15. doi:10.1016/j.canlet.2003.12.012 PubMedCrossRef

11.

Xi SC, Siu SW, Fong SW, Shiu SY (2001) Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 46:52–61. doi:10.1002/1097-0045(200101)46:1<52:AID-PROS1008>3.0.CO;2-Z PubMedCrossRef

12.

Sainz RM, Mayo JC, Tan DX, León J, Manchester L, Reiter RJ (2005) Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 63:29–43. doi:10.1002/pros.20155 PubMedCrossRef

13.

Karasek M, Carrillo-Vico A, Guerrero JM, Winczyk K, Pawlikowski M (2002) Expression of melatonin MT(1) and MT(2) receptors, and ROR alpha(1) receptor in transplantable murine Colon 38 cancer. Neuro Endocrinol Lett 23:55–60PubMed

14.

Bartsch H, Buchberger A, Franz H, Bartsch C, Maidonis I, Mecke D, Bayer E (2000) Effect of melatonin and pineal extracts on human ovarian and mammary tumor cells in a chemosensitivity assay. Life Sci 67:2953–2960. doi:10.1016/S0024-3205(00)00882-1 PubMedCrossRef

15.

Kobayashi Y, Itoh MT, Kondo H, Okuma Y, Sato S, Kanishi Y, Hamada N, Kiguchi K, Ishizuka B (2003) Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. J Pineal Res 35:71–74. doi:10.1046/j.1439-0434.2002.00691_2.x-i1 PubMed

16.

Blask DE, Dauchy RT, Sauer LA, Krause JA (2004) Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 25:951–960. doi:10.1093/carcin/bgh090 PubMedCrossRef

17.

Leja-Szpak A, Jaworek J, Pierzchalski P, Reiter RJ (2010) Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 49:248–255. doi:10.1111/j.1600-079X.2010.00789.x PubMedCrossRef

18.

Ying SW, Niles LP, Crocker C (1993) Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol 246:89–96PubMedCrossRef

19.

Kadekaro AL, Andrade LN, Floeter-Winter LM, Rollag MD, Virador V, Vieira W, Castrucci AM (2004) MT-1 melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells. J Pineal Res 36:204–211. doi:10.1111/j.1600-079X.2004-00119.x PubMedCrossRef

20.

Fischer TW, Zmijewski MA, Zbytek B, Sweatman TW, Slominski RM, Wortsman J, Slominski A (2006) Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. Int J Oncol 29:665–672PubMed

21.

Nakamura E, Kozaki K, Tsuda H, Suzuki E, Pimkhaokham A, Yamamoto G, Irie T, Tachikawa T, Amagasa T, Inazawa J, Imoto I (2008) Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci 99:1390–1400. doi:10-1111/j.1349-7006.2008.00838.x PubMedCrossRef

22.

Martín V, Herrera F, Carrera-Gonzalez P, García-Santos G, Antolín I, Rodriguez-Blanco J, Rodriguez C (2006) Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 66:1081–1088. doi:10.1158/0008-5472.CAN-05-2354 PubMedCrossRef

23.

Mao L, Cheng Q, Guardiola-Lemaître B, Schuster-Klein C, Dong C, Lai L, Hill SM (2010) In vitro and in vivo antitumor activity of melatonin receptor agonists. J Pineal Res 49:210–221. doi:10.1111/j.1600-079X.2010.00781.x PubMedCrossRef

24.

González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Mateos S, Hill SM, Sánchez-Barceló EJ, Cos S (2007) Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol Rep 17:947–953PubMed

25.

Cos S, Sanchez-Barcelo E (1995) Melatonin inhibition of MCF-7 human breast cancer cells growth: influence of cell proliferation rate. Cancer Lett 93:207–212. doi:10.1016/0304-3835(96)03811-A PubMedCrossRef

26.

Lai L, Yuan L, Cheng Q, Dong C, Mao L, Hill SM (2009) Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res Treat 118:293–305. doi:10.1007/s10549-008-0220-1 PubMedCrossRef

27.

Blask DE, Hill SM, Orstead KM, Massa JS (1986) Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7,12-dimethylbenzanthracene-(DMBA)-induced mammary tumorigenesis. J Neural Transm 67:125–138PubMedCrossRef

28.

Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, Ruhoff MS (1999) New insights into melatonin regulation of cancer growth. Adv Exp Med Biol 460:337–343PubMedCrossRef

29.

Subramanian A, Kothari L (1991) Melatonin, a suppressor of spontaneous murine mammary tumors. J Pineal Res 10:136–140PubMedCrossRef

30.

Sanchez-Barcelo EJ, Mediavilla MD, Tucker HA (1990) Influence of melatonin on mammary gland growth: in vivo and in vitro studies. Proc Soc Exp Biol Med 194:103–107PubMed

31.

Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, Lai L, Hill SM (2002) Involvement of the MT1 melatonin receptor in human breast cancer. Cancer Lett 179:141–150PubMedCrossRef

32.

Kiefer T, Ram PT, Yuan L, Hill SM (2002) Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 71:37–45. doi:10.1023/A:1013301408464 PubMedCrossRef

33.

Brydon L, Roka F, Petit L, de Coppet P, Tissot M, Barrett P, Morgan PJ, Nanoff C, Strosberg AD, Jockers R (1999) Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3) and G(q/11) proteins. Mol Endocrinol 13:2025–2038. doi:10.1210/me.13.12.2005 PubMedCrossRef

34.

Dillon DC, Easley SE, Asch BB, Cheney RT, Brydon L, Jockers R, Winston JS, Brooks JS, Hurd T, Asch HL (2002) Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant breast tissue. Am J Clin Pathol 118:451–458PubMedCrossRef

35.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100:8418–8423. doi:10.1073/pnas.0932692100 PubMedCrossRef

36.

Fadare O, Tavassoli FA (2007) The phenotypic spectrum of basal-like breast cancers: a critical appraisal (Review). Adv Anat Pathol 14:358–373. doi:10.1097/PAP.06013e31814b26fe PubMedCrossRef

37.

Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938–1948PubMedCrossRef

38.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376. doi:10.1158/1078-0432.CCR-07-1658 PubMedCrossRef

39.

Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O’Regan RM, Gabram SG, Eley JW (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370. doi:10.1007/s10549-008-9926-3 PubMedCrossRef

40.

Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, Villarreal-Garza C, González-Angulo AM, Bargalló E, Aguilar JL, Mohar A, Arrieta Ó (2011) Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 117:3658–3669. doi:10.1002/cncr.25961 PubMedCrossRef

41.

Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX (2009) Melatonin an established antioxidant worthy of use in clinical trials. Mol Med 15:43–50. doi:10.2119/molmed.2008.00117 PubMed

42.

Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni GJ (1996) Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 53:43–46PubMedCrossRef

43.

Lissoni P, Barni S, Mandalà M, Avdizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G (1999) Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumor patients with poor clinical status. Eur J Cancer 35:1688–1692. doi:10.1016/S0959-8049(99)00159-8 PubMedCrossRef

44.

Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ (2001) Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett 22:45–47PubMed

45.

Panzer A, Viljoen M (1997) The validity of melatonin as an oncostatic agent. J Pineal Res 22:184–202PubMedCrossRef

46.

Hrushesky WJM (2001) Melatonin in cancer therapy. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D (eds) The pineal gland and cancer. Spring, Berlin, pp 476–508CrossRef

47.

Contal C, O’Quigley J (1999) An application of changepoint methods in studying the effect of age on survival in breast cancer. Comp Stat Data Anal 30:253–270. doi:10.1016/S0167-9473(98)00096-6 CrossRef

48.

Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K (1982) A prognostic index in primary breast cancer. Br J Cancer 45:361–366PubMedCrossRef

49.

Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, Green VL, Brawley OW, Oprea-Ilies GM, Gabram SG (2008) High prevalence of triple-negative tumors in an urban cancer center. Cancer 113:608–615. doi:10.1002/cncr.23569 PubMedCrossRef

50.

Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea-Ilies G, Bayakly AR, O’Regan RM, Vertino PM, Eley JW (2010) Age/race differences in Her2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer 116:2549–2559. doi:10.1002/cncr.25016 PubMed

51.

Sullivan HC, Oprea G, Adams A, Page AJ, Cohen C (2012) Triple negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome. Appl Immunohistochem Mol Morphol (in print)

52.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502. doi:10.1001/jama.295.21.2492 PubMedCrossRef

53.

Williams JD, Cohen C, Darrow M, Page AJ, Chastain B, Adams AL (2011) Proliferation (Ki-67 and phosphohistone H3) and oncotype Dx recurrence score in estrogen receptor-positive breast cancer. Appl Immunohistochem Mol Morphol 19:431–436. doi:10.1097/PAI.0b013e318206d23d PubMedCrossRef

54.

Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM (2012) Routine pathologic parameters can predict oncotype Dx recurrence scores in subsets of ER positive patients who does not always need testing. Breast Cancer Res Treat 131:413–424. doi:10.1007/s10549-011-1416-3 PubMedCrossRef

55.

Tischkowitz M, Brunet J-S, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134. doi:10.1186/1471-2407-7-134 PubMedCrossRef

56.

Schernhammer ES, Hankinson SE (2005) Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 97:1084–1087. doi:10.1093/jnci/dji190 PubMedCrossRef

57.

Stevens RG (1987) Electric power use and breast cancer: a hypothesis (Review and Commentary). Am J Epidemiol 125:556–561PubMed

58.

Stevens RG (2009) Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int J Epidemiol 38:963–970. doi:10.1093/ije/dyp178 PubMedCrossRef

59.

Costa G, Haus E, Stevens R (2010) Shift work and cancer—considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health 36:163–179. doi:10.5271/sjweh.2899 PubMedCrossRef

60.

International Agency for Research in Cancer (IARC) (2010) Monographs on the evaluation of carcinogenic risks to humans, vol 98: painting, firefighting and shiftwork. IARC, Lyon

61.

Harth V, Bruning T, Rabstein S, Spickenheuser A, Bonberg N, Pesch B, Pallapies D (2011) Night-work and estrogen receptor status. In: Proceedings of the 20th international symposium on shiftwork and working time, Stockholm, Sweden, 28 June–1 July 2011

62.

Danforth DN Jr, Tamarkin L, Mulvihill JJ, Bagley CS, Lippman ME (1985) Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol 3:941–948PubMed

63.

Hill SM, Blask DE, Xiang S, Yuan L, Mao L, Dauchy RT, Dauchy EM, Frasch T, Duplesis T (2011) Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer (Review). J Mammary Gland Biol Neoplasia 16:235–245. doi:10.1007/S10911-011-9222-4 PubMedCrossRef

64.

Blask DE, Hill SM, Dauchy RT, Xiang S, Yuan L, Duplessis T, Mao L, Dauchy E, Sauer LA (2011) Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J Pineal Res 51:259–269. doi:10.1111/j.1600-079X.2011.00888.x PubMedCrossRef

65.

Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ (2010) Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 17:4462–4481PubMedCrossRef

66.

Girgert R, Hanf V, Emons G, Gründker C (2009) Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res 47:23–31. doi:10.1111/j.1600-079X.2009.00684.x PubMedCrossRef

67.

Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM (2002) MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 192:147–156. doi:10.1016/S0303-7207(02)00029-1 PubMedCrossRef

68.

Collins A, Yuan L, Kiefer TL, Cheng Q, Lai L, Hill SM (2003) Over-expression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett 189:49–57PubMedCrossRef

69.

Rivara S, Mor M, Bedini A, Spadoni G, Tavzia G (2008) Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders (Review). Curr Top Med Chem 8:954–968PubMedCrossRef

70.

Rajaratnam SMW, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB (2009) Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomized controlled multicenter trials. Lancet 373:482–491. doi:10.1016/S0140-6736(08)61812-7 PubMedCrossRef

71.

Jawed S, Kim B, Ottenhof T, Brown GM, Werstiuk ES, Niles LP (2007) Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol 560:17–22. doi:10.1016/j.ejphar.2007.01.022 PubMedCrossRef

72.

Cinatl J Jr, Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Kornhuber B, Schwabe D (1997) Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 8:958–963PubMedCrossRef

73.

Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969–6978. doi:10.1093/emboj/20.24.6969 PubMedCrossRef

74.

Olsen CM, Meussen-Elholm ET, Røste LS, Taubøll E (2004) Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7. Mol Cell Endocrinol 213:173–179. doi:10.1016/j.mce.2003.10.032 PubMedCrossRef

75.

Jung M (2001) Inhibitors of histone deacetylase as new anticancer agents (Review). Curr Med Chem 8:1505–1511PubMedCrossRef

76.

Blaheta RA, Cinatl J Jr (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22:492–511. doi:10.1002/med.10017 PubMedCrossRef

77.

Wang YM, Jin BZ, Ai F, Duan CH, Lu YZ, Dong TF, Fu QL (2012) The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol 69:1213–1220. doi:10.1007/s00280-012-1828-8 PubMedCrossRef

78.

Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E (2011) Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. doi:10.1177/1534735411425484

79.

Carillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ (2005) A review of the multiple actions of melatonin on the immune system. Endocrine 27(2):189–200. doi:10.1385/ENDO:27:2:189 CrossRef

Title: Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival
Authors: Gabriela Oprea-Ilies
Erhard Haus
Linda Sackett-Lundeen
Yuan Liu
Lauren McLendon
Robert Busch
Amy Adams
Cynthia Cohen
Publication date: 01-02-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2371-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

IL-21 gene polymorphism is associated with the prognosis of breast cancer in Chinese populations

Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages

Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communication

High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival

Supplement use during an intergroup clinical trial for breast cancer (S0221)

2-Hydroxycinnamaldehyde inhibits the epithelial-mesenchymal transition in breast cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer